CN1751129B - 利用基因表达图谱鉴定、监测和治疗传染病和表征传染病相关炎症 - Google Patents
利用基因表达图谱鉴定、监测和治疗传染病和表征传染病相关炎症 Download PDFInfo
- Publication number
- CN1751129B CN1751129B CN200380109850.5A CN200380109850A CN1751129B CN 1751129 B CN1751129 B CN 1751129B CN 200380109850 A CN200380109850 A CN 200380109850A CN 1751129 B CN1751129 B CN 1751129B
- Authority
- CN
- China
- Prior art keywords
- group
- component
- spectrum data
- sample
- experimenter
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 208000015181 infectious disease Diseases 0.000 title claims abstract description 155
- 230000004968 inflammatory condition Effects 0.000 title abstract description 6
- 208000035473 Communicable disease Diseases 0.000 title abstract description 5
- 230000014509 gene expression Effects 0.000 title description 251
- 238000011282 treatment Methods 0.000 title description 41
- 238000012544 monitoring process Methods 0.000 title description 20
- 238000012512 characterization method Methods 0.000 title description 4
- 238000000034 method Methods 0.000 claims abstract description 87
- 230000003321 amplification Effects 0.000 claims abstract description 47
- 238000003199 nucleic acid amplification method Methods 0.000 claims abstract description 47
- 238000005259 measurement Methods 0.000 claims abstract description 5
- 206010061218 Inflammation Diseases 0.000 claims description 160
- 230000004054 inflammatory process Effects 0.000 claims description 160
- 238000001228 spectrum Methods 0.000 claims description 138
- 239000003153 chemical reaction reagent Substances 0.000 claims description 37
- 208000024891 symptom Diseases 0.000 claims description 37
- 239000000203 mixture Substances 0.000 claims description 31
- 230000009885 systemic effect Effects 0.000 claims description 21
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 18
- 201000010099 disease Diseases 0.000 claims description 17
- 230000008569 process Effects 0.000 claims description 17
- 238000002360 preparation method Methods 0.000 claims description 15
- 238000003860 storage Methods 0.000 claims description 12
- 238000013507 mapping Methods 0.000 claims description 9
- 238000012207 quantitative assay Methods 0.000 claims description 6
- 101000959794 Homo sapiens Interferon alpha-2 Proteins 0.000 claims description 5
- 102100040018 Interferon alpha-2 Human genes 0.000 claims description 5
- 230000002969 morbid Effects 0.000 claims description 5
- 230000000052 comparative effect Effects 0.000 claims description 2
- 102100022712 Alpha-1-antitrypsin Human genes 0.000 claims 4
- 102000016605 B-Cell Activating Factor Human genes 0.000 claims 4
- 108010028006 B-Cell Activating Factor Proteins 0.000 claims 4
- 102100039928 Gamma-interferon-inducible protein 16 Human genes 0.000 claims 4
- 102100040352 Heat shock 70 kDa protein 1A Human genes 0.000 claims 4
- 101000823116 Homo sapiens Alpha-1-antitrypsin Proteins 0.000 claims 4
- 101000960209 Homo sapiens Gamma-interferon-inducible protein 16 Proteins 0.000 claims 4
- 101001037759 Homo sapiens Heat shock 70 kDa protein 1A Proteins 0.000 claims 4
- 101000599852 Homo sapiens Intercellular adhesion molecule 1 Proteins 0.000 claims 4
- 101001076418 Homo sapiens Interleukin-1 receptor type 1 Proteins 0.000 claims 4
- 101000990902 Homo sapiens Matrix metalloproteinase-9 Proteins 0.000 claims 4
- 102100037877 Intercellular adhesion molecule 1 Human genes 0.000 claims 4
- 102100026016 Interleukin-1 receptor type 1 Human genes 0.000 claims 4
- 102100030412 Matrix metalloproteinase-9 Human genes 0.000 claims 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 abstract description 59
- 239000000470 constituent Substances 0.000 abstract description 3
- 102000040650 (ribonucleotides)n+m Human genes 0.000 abstract 1
- 239000000523 sample Substances 0.000 description 167
- 210000004369 blood Anatomy 0.000 description 58
- 239000008280 blood Substances 0.000 description 58
- 210000004027 cell Anatomy 0.000 description 57
- 108090000623 proteins and genes Proteins 0.000 description 56
- 230000002068 genetic effect Effects 0.000 description 53
- 239000003814 drug Substances 0.000 description 43
- 230000006870 function Effects 0.000 description 43
- 238000006243 chemical reaction Methods 0.000 description 40
- 239000003795 chemical substances by application Substances 0.000 description 36
- 230000000875 corresponding effect Effects 0.000 description 34
- 238000001514 detection method Methods 0.000 description 33
- 206010039073 rheumatoid arthritis Diseases 0.000 description 32
- 241000894006 Bacteria Species 0.000 description 31
- 230000000694 effects Effects 0.000 description 26
- 230000001717 pathogenic effect Effects 0.000 description 25
- 238000012360 testing method Methods 0.000 description 24
- 238000002560 therapeutic procedure Methods 0.000 description 23
- 210000001519 tissue Anatomy 0.000 description 23
- 229940079593 drug Drugs 0.000 description 22
- 150000001875 compounds Chemical class 0.000 description 21
- 230000036541 health Effects 0.000 description 18
- 208000038016 acute inflammation Diseases 0.000 description 16
- 230000006022 acute inflammation Effects 0.000 description 16
- 210000001124 body fluid Anatomy 0.000 description 15
- 239000010839 body fluid Substances 0.000 description 15
- 238000004422 calculation algorithm Methods 0.000 description 14
- 230000000968 intestinal effect Effects 0.000 description 14
- 230000008520 organization Effects 0.000 description 14
- 230000008859 change Effects 0.000 description 13
- 238000003745 diagnosis Methods 0.000 description 13
- 239000002158 endotoxin Substances 0.000 description 13
- 238000000338 in vitro Methods 0.000 description 13
- 229920006008 lipopolysaccharide Polymers 0.000 description 13
- 239000000047 product Substances 0.000 description 13
- 206010051379 Systemic Inflammatory Response Syndrome Diseases 0.000 description 12
- 239000002299 complementary DNA Substances 0.000 description 12
- 238000002474 experimental method Methods 0.000 description 12
- 230000037396 body weight Effects 0.000 description 11
- 235000016709 nutrition Nutrition 0.000 description 11
- 230000035764 nutrition Effects 0.000 description 11
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 10
- 238000005516 engineering process Methods 0.000 description 10
- 239000012530 fluid Substances 0.000 description 10
- 210000002216 heart Anatomy 0.000 description 10
- 239000007788 liquid Substances 0.000 description 10
- 229960000485 methotrexate Drugs 0.000 description 10
- 229960004618 prednisone Drugs 0.000 description 10
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 10
- 238000005070 sampling Methods 0.000 description 10
- 230000001225 therapeutic effect Effects 0.000 description 10
- 206010035664 Pneumonia Diseases 0.000 description 9
- 230000036772 blood pressure Effects 0.000 description 9
- 206010014665 endocarditis Diseases 0.000 description 9
- 238000007689 inspection Methods 0.000 description 9
- 230000000770 proinflammatory effect Effects 0.000 description 9
- 230000004044 response Effects 0.000 description 9
- 208000019206 urinary tract infection Diseases 0.000 description 9
- 241000233866 Fungi Species 0.000 description 8
- 101001033249 Homo sapiens Interleukin-1 beta Proteins 0.000 description 8
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 8
- 102100039065 Interleukin-1 beta Human genes 0.000 description 8
- 238000011156 evaluation Methods 0.000 description 8
- 229960001680 ibuprofen Drugs 0.000 description 8
- 244000005700 microbiome Species 0.000 description 8
- 230000009467 reduction Effects 0.000 description 8
- 208000030852 Parasitic disease Diseases 0.000 description 7
- 238000003556 assay Methods 0.000 description 7
- 238000009826 distribution Methods 0.000 description 7
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 7
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 7
- 230000037081 physical activity Effects 0.000 description 7
- 238000012545 processing Methods 0.000 description 7
- 230000000638 stimulation Effects 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- 230000009385 viral infection Effects 0.000 description 7
- 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 description 6
- 206010061217 Infestation Diseases 0.000 description 6
- 241000700605 Viruses Species 0.000 description 6
- 239000000284 extract Substances 0.000 description 6
- 239000012678 infectious agent Substances 0.000 description 6
- 230000002757 inflammatory effect Effects 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 244000052769 pathogen Species 0.000 description 6
- 235000018102 proteins Nutrition 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 230000000630 rising effect Effects 0.000 description 6
- 230000004936 stimulating effect Effects 0.000 description 6
- 229940046728 tumor necrosis factor alpha inhibitor Drugs 0.000 description 6
- 239000002451 tumor necrosis factor inhibitor Substances 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- 101001002634 Homo sapiens Interleukin-1 alpha Proteins 0.000 description 5
- 102000003814 Interleukin-10 Human genes 0.000 description 5
- 108090000174 Interleukin-10 Proteins 0.000 description 5
- 206010040047 Sepsis Diseases 0.000 description 5
- 238000013461 design Methods 0.000 description 5
- 238000000605 extraction Methods 0.000 description 5
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 5
- 238000003384 imaging method Methods 0.000 description 5
- 230000002503 metabolic effect Effects 0.000 description 5
- 108020004707 nucleic acids Proteins 0.000 description 5
- 102000039446 nucleic acids Human genes 0.000 description 5
- 230000005855 radiation Effects 0.000 description 5
- 229940116176 remicade Drugs 0.000 description 5
- 208000013223 septicemia Diseases 0.000 description 5
- 238000002562 urinalysis Methods 0.000 description 5
- 230000004544 DNA amplification Effects 0.000 description 4
- 206010017523 Fungaemia Diseases 0.000 description 4
- 102100020881 Interleukin-1 alpha Human genes 0.000 description 4
- 206010058874 Viraemia Diseases 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 239000002260 anti-inflammatory agent Substances 0.000 description 4
- 239000012472 biological sample Substances 0.000 description 4
- 230000003203 everyday effect Effects 0.000 description 4
- 108020004999 messenger RNA Proteins 0.000 description 4
- 150000007523 nucleic acids Chemical class 0.000 description 4
- 235000015097 nutrients Nutrition 0.000 description 4
- 230000035479 physiological effects, processes and functions Effects 0.000 description 4
- 235000004252 protein component Nutrition 0.000 description 4
- 238000003753 real-time PCR Methods 0.000 description 4
- 238000010839 reverse transcription Methods 0.000 description 4
- 238000000926 separation method Methods 0.000 description 4
- 150000003431 steroids Chemical class 0.000 description 4
- 230000002103 transcriptional effect Effects 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 3
- 101000599940 Homo sapiens Interferon gamma Proteins 0.000 description 3
- 102100037850 Interferon gamma Human genes 0.000 description 3
- 208000003435 Optic Neuritis Diseases 0.000 description 3
- 241000193996 Streptococcus pyogenes Species 0.000 description 3
- 230000003110 anti-inflammatory effect Effects 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- 238000004891 communication Methods 0.000 description 3
- 230000002860 competitive effect Effects 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 238000009795 derivation Methods 0.000 description 3
- 229960003957 dexamethasone Drugs 0.000 description 3
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 238000009413 insulation Methods 0.000 description 3
- 230000036651 mood Effects 0.000 description 3
- 238000004393 prognosis Methods 0.000 description 3
- 230000009257 reactivity Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 230000035945 sensitivity Effects 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 238000010561 standard procedure Methods 0.000 description 3
- 238000007619 statistical method Methods 0.000 description 3
- 239000003053 toxin Substances 0.000 description 3
- 231100000765 toxin Toxicity 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 2
- 241000709661 Enterovirus Species 0.000 description 2
- 108010008165 Etanercept Proteins 0.000 description 2
- 108020005004 Guide RNA Proteins 0.000 description 2
- 102000003810 Interleukin-18 Human genes 0.000 description 2
- 108090000171 Interleukin-18 Proteins 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 101710163270 Nuclease Proteins 0.000 description 2
- 238000002123 RNA extraction Methods 0.000 description 2
- 206010057190 Respiratory tract infections Diseases 0.000 description 2
- 102000006382 Ribonucleases Human genes 0.000 description 2
- 108010083644 Ribonucleases Proteins 0.000 description 2
- 206010046306 Upper respiratory tract infection Diseases 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 238000004590 computer program Methods 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 229910003460 diamond Inorganic materials 0.000 description 2
- 239000010432 diamond Substances 0.000 description 2
- 229940073621 enbrel Drugs 0.000 description 2
- 230000001506 immunosuppresive effect Effects 0.000 description 2
- 208000027866 inflammatory disease Diseases 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 230000005055 memory storage Effects 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 244000045947 parasite Species 0.000 description 2
- 230000008288 physiological mechanism Effects 0.000 description 2
- 231100000614 poison Toxicity 0.000 description 2
- 230000007096 poisonous effect Effects 0.000 description 2
- -1 polypropylene Polymers 0.000 description 2
- ZCCUUQDIBDJBTK-UHFFFAOYSA-N psoralen Chemical compound C1=C2OC(=O)C=CC2=CC2=C1OC=C2 ZCCUUQDIBDJBTK-UHFFFAOYSA-N 0.000 description 2
- 238000012887 quadratic function Methods 0.000 description 2
- 238000003908 quality control method Methods 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 238000003757 reverse transcription PCR Methods 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 230000033764 rhythmic process Effects 0.000 description 2
- 239000003161 ribonuclease inhibitor Substances 0.000 description 2
- 238000011125 single therapy Methods 0.000 description 2
- 230000004797 therapeutic response Effects 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000002110 toxicologic effect Effects 0.000 description 2
- 230000003442 weekly effect Effects 0.000 description 2
- 101150016096 17 gene Proteins 0.000 description 1
- 108020004463 18S ribosomal RNA Proteins 0.000 description 1
- 101150090724 3 gene Proteins 0.000 description 1
- 101150034014 48 gene Proteins 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- 102100039398 C-X-C motif chemokine 2 Human genes 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 102100037077 Complement C1q subcomponent subunit A Human genes 0.000 description 1
- 241001481833 Coryphaena hippurus Species 0.000 description 1
- 102000016736 Cyclin Human genes 0.000 description 1
- 108050006400 Cyclin Proteins 0.000 description 1
- 230000004543 DNA replication Effects 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 1
- 102100034221 Growth-regulated alpha protein Human genes 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 101000889128 Homo sapiens C-X-C motif chemokine 2 Proteins 0.000 description 1
- 101000740726 Homo sapiens Complement C1q subcomponent subunit A Proteins 0.000 description 1
- 101001069921 Homo sapiens Growth-regulated alpha protein Proteins 0.000 description 1
- 101001097889 Homo sapiens Platelet-activating factor acetylhydrolase Proteins 0.000 description 1
- 101000795167 Homo sapiens Tumor necrosis factor receptor superfamily member 13B Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 206010027336 Menstruation delayed Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- FQISKWAFAHGMGT-SGJOWKDISA-M Methylprednisolone sodium succinate Chemical compound [Na+].C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)COC(=O)CCC([O-])=O)CC[C@H]21 FQISKWAFAHGMGT-SGJOWKDISA-M 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 241001040659 Plasmodium (Plasmodium) Species 0.000 description 1
- 102100037518 Platelet-activating factor acetylhydrolase Human genes 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 238000010802 RNA extraction kit Methods 0.000 description 1
- 239000013614 RNA sample Substances 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 108700008625 Reporter Genes Proteins 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- 241000223104 Trypanosoma Species 0.000 description 1
- 102100040247 Tumor necrosis factor Human genes 0.000 description 1
- 102100029675 Tumor necrosis factor receptor superfamily member 13B Human genes 0.000 description 1
- 102100029469 WD repeat and HMG-box DNA-binding protein 1 Human genes 0.000 description 1
- 101710097421 WD repeat and HMG-box DNA-binding protein 1 Proteins 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000003416 augmentation Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000001447 compensatory effect Effects 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 238000013016 damping Methods 0.000 description 1
- 238000013500 data storage Methods 0.000 description 1
- 230000009849 deactivation Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 238000003255 drug test Methods 0.000 description 1
- 241001493065 dsRNA viruses Species 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 230000002996 emotional effect Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 210000001508 eye Anatomy 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 239000012520 frozen sample Substances 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 210000005256 gram-negative cell Anatomy 0.000 description 1
- 210000005255 gram-positive cell Anatomy 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 210000003677 hemocyte Anatomy 0.000 description 1
- 229940000351 hemocyte Drugs 0.000 description 1
- 210000000087 hemolymph Anatomy 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000011221 initial treatment Methods 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 230000002934 lysing effect Effects 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 238000007620 mathematical function Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 208000035824 paresthesia Diseases 0.000 description 1
- 238000001050 pharmacotherapy Methods 0.000 description 1
- 230000010399 physical interaction Effects 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000000955 prescription drug Substances 0.000 description 1
- 238000007639 printing Methods 0.000 description 1
- 210000004908 prostatic fluid Anatomy 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000000941 radioactive substance Substances 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 230000000452 restraining effect Effects 0.000 description 1
- 238000007790 scraping Methods 0.000 description 1
- 230000001932 seasonal effect Effects 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 239000004065 semiconductor Substances 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 229940087854 solu-medrol Drugs 0.000 description 1
- 230000000392 somatic effect Effects 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 230000003637 steroidlike Effects 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 238000005382 thermal cycling Methods 0.000 description 1
- 230000036962 time dependent Effects 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 238000013389 whole blood assay Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/136—Screening for pharmacological compounds
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Wood Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Pathology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US43525702P | 2002-12-19 | 2002-12-19 | |
| US60/435,257 | 2002-12-19 | ||
| PCT/US2003/040551 WO2004057034A1 (en) | 2002-12-19 | 2003-12-19 | Identification, monitoring and treatment of infectious disease and characterization of inflammatory conditions related to infectious disease using gene expression profiles |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1751129A CN1751129A (zh) | 2006-03-22 |
| CN1751129B true CN1751129B (zh) | 2014-07-23 |
Family
ID=32682206
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN200380109850.5A Expired - Lifetime CN1751129B (zh) | 2002-12-19 | 2003-12-19 | 利用基因表达图谱鉴定、监测和治疗传染病和表征传染病相关炎症 |
Country Status (8)
| Country | Link |
|---|---|
| EP (1) | EP1579008A1 (enExample) |
| JP (2) | JP2006510382A (enExample) |
| CN (1) | CN1751129B (enExample) |
| AU (1) | AU2003303238B2 (enExample) |
| BR (1) | BR0317612A (enExample) |
| CA (1) | CA2511237A1 (enExample) |
| MX (1) | MXPA05006804A (enExample) |
| WO (1) | WO2004057034A1 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2505921A1 (en) | 2002-11-12 | 2004-05-27 | Becton, Dickinson And Company | Diagnosis of sepsis or sirs using biomarker profiles |
| EP2128270B1 (en) | 2003-08-08 | 2012-10-03 | Genenews Inc. | Osteoarthritis biomarkers and uses thereof |
| BRPI0609302A2 (pt) | 2005-04-15 | 2011-10-11 | Becton Dickinson Co | métodos para prever o desenvolvimento de sepse e para diagnosticar sepse em um indivìduo a ser testado, microarranjo, kit para prever o desenvolvimento de sepse em um indivìduo a ser testado, produto de programa de computador, computador, sistema de computador para determinar se um indivìduo é susceptìvel de desenvolver sepse, sinal digital embutido em uma onda portadora, e, interface gráfica de usuário para determinar se um indivìduo é susceptìvel de desenvolver sepse |
| AU2006294477A1 (en) * | 2005-09-27 | 2007-04-05 | Source Mdx | Gene expression profiling for identification monitoring and treatment of rheumatoid arthritis |
| CA2652239A1 (en) * | 2006-05-16 | 2007-11-29 | Source Mdx | Assessment of effect of an agent on a human biological condition using rodent gene expression panels |
| WO2008048986A2 (en) * | 2006-10-17 | 2008-04-24 | Children's Hospital Medical Center | Gene array technique for predicting response in inflammatory bowel diseases |
| DE102007036678B4 (de) * | 2007-08-03 | 2015-05-21 | Sirs-Lab Gmbh | Verwendung von Polynukleotiden zur Erfassung von Genaktivitäten für die Unterscheidung zwischen lokaler und systemischer Infektion |
| TWI600759B (zh) | 2010-04-02 | 2017-10-01 | 可娜公司 | 藉由抑制群落刺激因子３（ｃｓｆ３）之天然反義轉錄物以治療ｃｓｆ３相關疾病 |
| GB201304626D0 (en) * | 2013-03-14 | 2013-05-01 | Univ Cardiff | Method of identifying a bacterial infection |
| BR112017019373A2 (pt) * | 2015-03-12 | 2018-06-05 | Koninklijke Philips N.V. | método implementado por computador, e, mídia legível por computador |
| US11031119B2 (en) * | 2019-11-13 | 2021-06-08 | Cube Click, Inc. | Dental images processed with deep learning for national security |
| CN118824376B (zh) * | 2024-09-18 | 2025-01-21 | 江苏省疾病预防控制中心(江苏省预防医学科学院) | 基于元学习技术的呼吸系统传染病人工智能辅助筛查系统 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0960214A4 (en) * | 1996-12-06 | 2004-08-04 | Urocor Inc | Diagnosis of disease status on HAnd from mRNA profiles |
| DK1198585T3 (da) * | 1999-06-28 | 2007-10-15 | Source Precision Medicine Inc | Fremgangsmåde til karakterisering af en biologisk tilstand ved anvendelse af kalibrerede genudtrykkelsesprofiler |
| US6964850B2 (en) * | 2001-11-09 | 2005-11-15 | Source Precision Medicine, Inc. | Identification, monitoring and treatment of disease and characterization of biological condition using gene expression profiles |
-
2003
- 2003-12-19 AU AU2003303238A patent/AU2003303238B2/en not_active Ceased
- 2003-12-19 CN CN200380109850.5A patent/CN1751129B/zh not_active Expired - Lifetime
- 2003-12-19 MX MXPA05006804A patent/MXPA05006804A/es unknown
- 2003-12-19 EP EP03808491A patent/EP1579008A1/en not_active Withdrawn
- 2003-12-19 BR BR0317612-6A patent/BR0317612A/pt not_active IP Right Cessation
- 2003-12-19 WO PCT/US2003/040551 patent/WO2004057034A1/en not_active Ceased
- 2003-12-19 CA CA002511237A patent/CA2511237A1/en not_active Abandoned
- 2003-12-19 JP JP2004562300A patent/JP2006510382A/ja active Pending
-
2010
- 2010-05-13 JP JP2010111560A patent/JP2010227111A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2003303238B2 (en) | 2010-07-22 |
| CN1751129A (zh) | 2006-03-22 |
| JP2010227111A (ja) | 2010-10-14 |
| EP1579008A1 (en) | 2005-09-28 |
| WO2004057034A1 (en) | 2004-07-08 |
| AU2003303238A1 (en) | 2004-07-14 |
| JP2006510382A (ja) | 2006-03-30 |
| MXPA05006804A (es) | 2006-03-30 |
| CA2511237A1 (en) | 2004-07-08 |
| BR0317612A (pt) | 2005-12-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102402650A (zh) | 利用基因表达分布图识别、监控和治疗疾病以及鉴定生物学状态 | |
| Kuiper et al. | Epigenetic and metabolomic biomarkers for biological age: a comparative analysis of mortality and frailty risk | |
| AU784233B2 (en) | Systems and methods for characterizing a biological condition or agent using calibrated gene expression profiles | |
| JP2010227111A (ja) | 遺伝子発現プロフィールを用いる、感染症の同定、モニタリング、および処置、ならびに感染症に関連する炎症状態の特徴付け | |
| EP2066809A2 (en) | Gene expression profiling for identification, monitoring and treatment of transplant rejection | |
| US10150982B2 (en) | Microbial ecology shift assay | |
| Baker et al. | Constraints on decision making: implications from genetics, personality, and addiction | |
| Peters et al. | Protective intravenous BCG vaccination induces enhanced immune signaling in the airways | |
| US20110306512A1 (en) | Gene Expression Profiling for Identification, Monitoring, and Treatment of Osteoarthritis | |
| JP2006510382A5 (enExample) | ||
| AU2003303238A2 (en) | Identification, monitoring and treatment of infectious disease and characterization of inflammatory conditions related to infectious disease using gene expression profiles | |
| CN105506074B (zh) | 一种用于精神分裂症诊断的lncRNA标志物及试剂盒 | |
| Mladenovic et al. | Evaluating frailty scores across experimental groups in rodent models: bridging physical and cognitive domains | |
| Zhou et al. | Gut microbiota mediating the effect of chronic kidney disease on cognitive dysfunction: a mendelian randomization study | |
| RU2715223C1 (ru) | Способ определения референтных значений показателей микроорганизмов, исследуемых методом хромато-масс-спектрометрии | |
| Kuiper et al. | Vo ino ic, D | |
| Zainal Abidin et al. | Let‐7e as Potential Diagnostic Biomarkers in Early Detection of Peri‐Implant Diseases: A Cross‐Sectional Study | |
| HK1169190A (en) | Identification, monitoring and treatment of disease and characterization of biological condition using gene expression profiles | |
| Armenian | Avoiding information bias in exposure assessment | |
| Baccarelli et al. | Blood Epigenetic Age may Predict Cancer Incidence and Mortality | |
| Russell et al. | CI Experimental Design Workshop Manual |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C12 | Rejection of a patent application after its publication | ||
| RJ01 | Rejection of invention patent application after publication |
Open date: 20060322 |
|
| ASS | Succession or assignment of patent right |
Owner name: LIFE TECHNOLOGIES CORPORATION Free format text: FORMER OWNER: SOURCE PREC MEDICINE INC. Effective date: 20120105 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20120105 Address after: California, USA Applicant after: LIFE TECHNOLOGIES Corp. Address before: American Colorado Applicant before: Source Precision Medicine, Inc. |
|
| CI01 | Publication of corrected invention patent application |
Correction item: Rejection of patent application Correct: Dismiss False: Reject Number: 31 Volume: 26 |
|
| ERR | Gazette correction |
Free format text: CORRECT: PATENT APPLICATION REJECTION OF AFTER PUBLICATION; FROM: REJECTION TO: REVOCATION REJECTED |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CX01 | Expiry of patent term | ||
| CX01 | Expiry of patent term |
Granted publication date: 20140723 |